Biomarker identified for likely aggressive, early stage breast cancer

The one-size-fits-all approach to early stage breast cancer creates a paradox: Millions of dollars are spent on unnecessary surgeries and radiation to treat women with low-risk ‘in situ’ lesions…

Be the first to comment

Leave a Reply

Your email address will not be published.


*